Evidence map›Paper›PMID 22558432›Full record

ArticlePloS one2012

The airway microbiota in cystic fibrosis: a complex fungal and bacterial community--implications for therapeutic management.

Laurence Delhaes, Sébastien Monchy, Emilie Fréalle, Christine Hubans, Julia Salleron, Sylvie Leroy, Anne Prevotat, Frédérick Wallet, Benoit Wallaert, Eduardo Dei-Cas and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
198citing papers in PubMed, 1 pooled it
28.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

198 citing papers in PubMed, 1 synthesis or guideline pooled it, 346 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. mSphere · 2026
    Article
  4. Review
  5. Review
  6. bioRxiv : the preprint server for biology · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Fungal lung disease.The European respiratory journal · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

138 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Laurence DelhaesCenter for Infection and Immunity of Lille (CIIL), Institut Pasteur de Lille, Biology and Diversity of Emerging Eukaryotic Pathogens (BDEEP), BP 245, Lille, France. Laurence.delhaes@pasteur-lille.fr
Sébastien Monchy
Emilie Fréalle
Christine Hubans
Julia Salleron
Sylvie Leroy
Anne Prevotat
Frédérick Wallet
Benoit Wallaert
Eduardo Dei-Cas
Telesphore Sime-Ngando
Magali Chabé
Eric Viscogliosi
Hôpital Albert Calmette · FRLille’s Cardiology Hospital · FRUniversité Lille Nord de France · FRCenter for Infection and Immunity of Lille · FRCentre National de la Recherche Scientifique · FRClermont Université · FRInstitut Pasteur · FRInstitut Pasteur de Lille · FRLaboratoire Microorganismes Génome et Environnement · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven the polymicrobial nature of pulmonary infections in patients with cystic fibrosis (CF), it is essential to enhance our knowledge on the composition of the microbial community to improve patient management. In this study, we developed a pyrosequencing approach to extensively explore the diversity and dynamics of fungal and prokaryotic populations in CF lower airways. METHODOLOGY AND PRINCIPAL

findingsFungi and bacteria diversity in eight sputum samples collected from four adult CF patients was investigated using conventional microbiological culturing and high-throughput pyrosequencing approach targeting the ITS2 locus and the 16S rDNA gene. The unveiled microbial community structure was compared to the clinical profile of the CF patients. Pyrosequencing confirmed recently reported bacterial diversity and observed complex fungal communities, in which more than 60% of the species or genera were not detected by cultures. Strikingly, the diversity and species richness of fungal and bacterial communities was significantly lower in patients with decreased lung function and poor clinical status. Values of Chao1 richness estimator were statistically correlated with values of the Shwachman-Kulczycki score, body mass index, forced vital capacity, and forced expiratory volume in 1 s (p = 0.046, 0.047, 0.004, and 0.001, respectively for fungal Chao1 indices, and p = 0.010, 0.047, 0.002, and 0.0003, respectively for bacterial Chao1 values). Phylogenetic analysis showed high molecular diversities at the sub-species level for the main fungal and bacterial taxa identified in the present study. Anaerobes were isolated with Pseudomonas aeruginosa, which was more likely to be observed in association with Candida albicans than with Aspergillus fumigatus.

conclusionsIn light of the recent concept of CF lung microbiota, we viewed the microbial community as a unique pathogenic entity. We thus interpreted our results to highlight the potential interactions between microorganisms and the role of fungi in the context of improving survival in CF.

Indexed as

Sequence Analysis, DNAAdultBacteriaBiodiversityCystic FibrosisDNA, BacterialDNA, FungalDNA, Ribosomal SpacerFemaleFungiHumansMaleMetagenomeRespiratory SystemDNA, BacterialDNA, FungalDNA, Ribosomal Spacer

Identifiers

PMID22558432
PMCPMC3338676
OpenAlexW2029374202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.